Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.

Magnano L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, Muntañola A, Nadeu F, Setoain X, Rodríguez S, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Sancho JM, Moreno M, Mercadal S, Carro I, Salar A, Garcia-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Jiménez-Ubieto A, Rodriguez A, González de Villambrosía S, Bello JL, López L, Novelli S, de Cabo E, Infante ME, Pardal E, Monsalvo S, González M, Martín A, Caballero MD, López-Guillermo A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO).

Br J Haematol. 2019 Feb 22. doi: 10.1111/bjh.15805. [Epub ahead of print]

PMID:
30793290
2.

Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.

Redondo AM, Valcárcel D, González-Rodríguez AP, Suárez-Lledó M, Bello JL, Canales M, Gayoso J, Colorado M, Jarque I, Del Campo R, Arranz R, Terol MJ, Rifón JJ, Rodríguez MJ, Ramírez MJ, Castro N, Sánchez A, López-Jiménez J, Montes-Moreno S, Briones J, López A, Palomera L, López-Guillermo A, Caballero D, Martín A; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO).

Br J Haematol. 2019 Mar;184(5):797-807. doi: 10.1111/bjh.15713. Epub 2018 Dec 12.

PMID:
30548583
3.

Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma.

Baptista MJ, Tapia G, Morgades M, Muncunill J, Muñoz-Marmol AM, Montoto S, Gribben JG, Calaminici M, Martinez A, Gonzalez-Farre B, Dlouhy I, González-Barca E, Terol MJ, Miralles P, Alcoceba M, Vall-Llovera F, Briones J, Abrisqueta P, Abella E, Provencio M, García-Ballesteros C, Moraleda JM, Sancho JM, Ribera JM, Mate JL, Navarro JT.

Leuk Lymphoma. 2018 Oct 15:1-5. doi: 10.1080/10428194.2018.1512711. [Epub ahead of print] No abstract available.

PMID:
30322315
4.

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N.

Haematologica. 2019 Mar;104(3):576-586. doi: 10.3324/haematol.2018.196931. Epub 2018 Sep 27.

5.

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy.

Trnĕný M, Verhoef G, Dyer MJ, Ben Yehuda D, Patti C, Canales M, Lopez A, Awan FT, Montgomery PG, Janikova A, Barbui AM, Sulek K, Terol MJ, Radford J, Guidetti A, Di Nicola M, Siraudin L, Hatteville L, Schwab S, Oprea C, Gianni AM.

Haematologica. 2018 Aug;103(8):1351-1358. doi: 10.3324/haematol.2017.168401. Epub 2018 May 10.

6.

Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation.

Piñana JL, Perez-Pitarch A, Guglieri-Lopez B, Giménez E, Hernandez-Boluda JC, Terol MJ, Ferriols-Lisart R, Solano C, Navarro D.

Am J Transplant. 2018 Dec;18(12):2885-2894. doi: 10.1111/ajt.14754. Epub 2018 Apr 24.

PMID:
29603596
7.

Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study.

Piñana JL, Madrid S, Pérez A, Hernández-Boluda JC, Giménez E, Terol MJ, Calabuig M, Navarro D, Solano C.

Biol Blood Marrow Transplant. 2018 Mar;24(3):563-570. doi: 10.1016/j.bbmt.2017.11.001. Epub 2017 Nov 15.

8.

The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.

Martínez-Trillos A, Pinyol M, Delgado J, Aymerich M, Rozman M, Baumann T, González-Díaz M, Hernández JM, Alcoceba M, Muntañola A, Terol MJ, Navarro B, Giné E, Jares P, Beà S, Navarro A, Colomer D, Nadeu F, Colado E, Payer AR, García-Cerecedo T, Puente XS, López-Otin C, Campo E, López-Guillermo A, Villamor N.

Leuk Lymphoma. 2018 Oct;59(10):2318-2326. doi: 10.1080/10428194.2017.1397660. Epub 2017 Nov 8.

PMID:
29115891
9.

Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?

Solano C, Mateo EM, Pérez A, Talaya A, Terol MJ, Albert E, Giménez E, Vinuesa V, Piñana JL, Boluda JCH, Navarro D.

J Clin Virol. 2017 Dec;97:26-32. doi: 10.1016/j.jcv.2017.10.016. Epub 2017 Nov 3.

PMID:
29096390
10.

Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.

Nadeu F, Clot G, Delgado J, Martín-García D, Baumann T, Salaverria I, Beà S, Pinyol M, Jares P, Navarro A, Suárez-Cisneros H, Aymerich M, Rozman M, Villamor N, Colomer D, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer ÁR, Puente XS, López-Otín C, López-Guillermo A, Enjuanes A, Campo E.

Leukemia. 2018 Mar;32(3):645-653. doi: 10.1038/leu.2017.291. Epub 2017 Sep 19.

11.

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions.

Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B.

Oncotarget. 2017 Apr 21;8(33):54297-54303. doi: 10.18632/oncotarget.17350. eCollection 2017 Aug 15.

12.

Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.

Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G, Mercadal S, Carro I, Sancho JM, Moreno M, Salar A, García-Pallarols F, Arranz R, Cannata J, Terol MJ, Teruel AI, Rodríguez A, Jiménez-Ubieto A, González de Villambrosia S, Bello JL, López L, Monsalvo S, Novelli S, de Cabo E, Infante MS, Pardal E, García-Álvarez M, Delgado J, González M, Martín A, López-Guillermo A, Caballero MD.

Br J Haematol. 2017 Sep;178(5):699-708. doi: 10.1111/bjh.14831. Epub 2017 Aug 7.

PMID:
28782811
13.

In the literature: February 2017.

Cervantes A, Terol MJ.

ESMO Open. 2017 Mar 24;2(1):e000171. doi: 10.1136/esmoopen-2017-000171. eCollection 2017. No abstract available.

14.

A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study.

Piñana JL, Hernández-Boluda JC, Calabuig M, Ballester I, Marín M, Madrid S, Teruel A, Terol MJ, Navarro D, Solano C.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12729. Epub 2017 Jul 17.

PMID:
28544152
15.

A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis.

Piñana JL, Perez-Pitarch A, Garcia-Cadenas I, Barba P, Hernandez-Boluda JC, Esquirol A, Fox ML, Terol MJ, Queraltó JM, Vima J, Valcarcel D, Ferriols-Lisart R, Sierra J, Solano C, Martino R.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1177-1185. doi: 10.1016/j.bbmt.2017.03.035. Epub 2017 Apr 7.

16.

Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance.

Baptista MJ, Granada I, Morgades M, Calasanz MJ, Canals J, Robles De Castro D, Luño E, Ruiz-Xivillé N, Rodríguez-Hernández I, González T, Terol MJ, Valiente A, Ortuño F, Garcia-Malo MD, Piñan MÁ, Oliveira AC, Talavera M, Buño I, Batlle-López A, Moreno C, Ferra C, Solé F.

Am J Hematol. 2017 Jul;92(7):E132-E135. doi: 10.1002/ajh.24754. Epub 2017 Jun 1. No abstract available.

17.

Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.

García-Marco JA, Delgado J, Hernández-Rivas JA, Ramírez Payer Á, Loscertales Pueyo J, Jarque I, Abrisqueta P, Giraldo P, Martínez R, Yáñez L, Terol MJ, González M, Bosch F; en nombre del Grupo Español de Leucemia Linfocítica Crónica (GELLC).

Med Clin (Barc). 2017 Apr 21;148(8):381.e1-381.e9. doi: 10.1016/j.medcli.2016.12.030. Epub 2017 Feb 22. English, Spanish.

PMID:
28236475
18.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.

Kekre N, Marquez-Malaver FJ, Cabrero M, Piñana J, Esquirol A, Soiffer RJ, Caballero D, Terol MJ, Martino R, Antin JH, Lopez-Corral L, Solano C, Armand P, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1808-1815. doi: 10.1016/j.bbmt.2016.07.006. Epub 2016 Jul 25.

19.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

20.

The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial).

Montesinos P, Cabrero M, Valcárcel D, Rovira M, García-Marco JA, Loscertales J, Moreno C, Duarte R, Terol MJ, Villamor N, Abrisqueta P, Caballero D, Sanz J, Delgado J.

Bone Marrow Transplant. 2016 Oct;51(10):1404-1407. doi: 10.1038/bmt.2016.145. Epub 2016 May 23. No abstract available.

PMID:
27214073
21.

Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO).

Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 May 17.

PMID:
27185197
22.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.

Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E.

Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.

23.

Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.

Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.

Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.

24.

Non-coding recurrent mutations in chronic lymphocytic leukaemia.

Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E.

Nature. 2015 Oct 22;526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22.

PMID:
26200345
25.

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.

Piñana JL, Sanz J, Esquirol A, Martino R, Picardi A, Barba P, Parody R, Gayoso J, Montesinos P, Guidi S, Terol MJ, Moscardó F, Solano C, Arcese W, Sanz MA, Sierra J, Sanz G; GETH GITMO groups.

Eur J Haematol. 2016 Feb;96(2):128-35. doi: 10.1111/ejh.12557. Epub 2015 Apr 18.

PMID:
25845981
26.

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.

Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, Rozman M, Colomer D, Delgado J, Giné E, González-Díaz M, Hernández-Rivas JM, Colado E, Rayón C, Payer AR, Terol MJ, Navarro B, Quesada V, Puente XS, Rozman C, López-Otín C, Campo E, López-Guillermo A, Villamor N.

Blood. 2014 Jun 12;123(24):3790-6. doi: 10.1182/blood-2013-12-543306. Epub 2014 Apr 29.

27.

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.

Abrisqueta P, Villamor N, Terol MJ, González-Barca E, González M, Ferrà C, Abella E, Delgado J, García-Marco JA, González Y, Carbonell F, Ferrer S, Monzó E, Jarque I, Muntañola A, Constants M, Escoda L, Calvo X, Bobillo S, Montoro JB, Montserrat E, Bosch F.

Blood. 2013 Dec 5;122(24):3951-9. doi: 10.1182/blood-2013-05-502773. Epub 2013 Oct 11.

28.

Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws.

Bagan J, Sáez GT, Tormos MC, Hens E, Terol MJ, Bagan L, Diaz-Fernández JM, Lluch A, Camps C.

Oral Dis. 2014 Jul;20(5):446-52. doi: 10.1111/odi.12150. Epub 2013 Jul 10.

PMID:
23837828
29.

First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.

Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA, Aláez C, Pérez-Calvo J, Martínez-Sánchez P, Sánchez-González B, Canales MA, Conde E, Martín A, Arranz E, Terol MJ, Salar A, Caballero D.

Haematologica. 2013 Oct;98(10):1563-70. doi: 10.3324/haematol.2013.088377. Epub 2013 Jun 10.

30.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group.

Leukemia. 2013 Oct;27(10):2056-61. doi: 10.1038/leu.2013.166. Epub 2013 Jun 7. Erratum in: Leukemia. 2013 Oct;27(10):2112.

PMID:
23743858
31.

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.

Van Den Neste E, Cazin B, Janssens A, González-Barca E, Terol MJ, Levy V, Pérez de Oteyza J, Zachee P, Saunders A, de Frias M, Campàs C.

Cancer Chemother Pharmacol. 2013 Mar;71(3):581-91. doi: 10.1007/s00280-012-2033-5. Epub 2012 Dec 11.

32.

Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.

Paiva B, Vídriales MB, Montalbán MÁ, Pérez JJ, Gutiérrez NC, Rosiñol L, Martínez-López J, Mateos MV, Cordón L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Lahuerta JJ, Bladé J, Orfao A, San Miguel JF.

Am J Pathol. 2012 Nov;181(5):1870-8. doi: 10.1016/j.ajpath.2012.07.020. Epub 2012 Sep 10.

PMID:
22974582
33.

A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds α4β1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells.

Ugarte-Berzal E, Bailón E, Amigo-Jiménez I, Vituri CL, del Cerro MH, Terol MJ, Albar JP, Rivas G, García-Marco JA, García-Pardo A.

J Biol Chem. 2012 Aug 10;287(33):27601-13. doi: 10.1074/jbc.M112.354670. Epub 2012 Jun 22.

34.

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.

Paiva B, Gutiérrez NC, Chen X, Vídriales MB, Montalbán MÁ, Rosiñol L, Oriol A, Martínez-López J, Mateos MV, López-Corral L, Díaz-Rodríguez E, Pérez JJ, Fernández-Redondo E, de Arriba F, Palomera L, Bengoechea E, Terol MJ, de Paz R, Martin A, Hernández J, Orfao A, Lahuerta JJ, Bladé J, Pandiella A, Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative.

Leukemia. 2012 Aug;26(8):1862-9. doi: 10.1038/leu.2012.42. Epub 2012 Feb 15.

PMID:
22333880
35.

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

Paiva B, Gutiérrez NC, Rosiñol L, Vídriales MB, Montalbán MÁ, Martínez-López J, Mateos MV, Cibeira MT, Cordón L, Oriol A, Terol MJ, Echeveste MA, de Paz R, de Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Sureda A, Gorosquieta A, Alegre A, Martin A, Hernández MT, Lahuerta JJ, Bladé J, San Miguel JF; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups.

Blood. 2012 Jan 19;119(3):687-91. doi: 10.1182/blood-2011-07-370460. Epub 2011 Nov 29.

36.

An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant.

Guillem VM, Arbona C, Hernández-Boluda JC, Terol MJ, Goterris R, Solano C, Tormo M.

Leuk Lymphoma. 2011 Jul;52(7):1249-54. doi: 10.3109/10428194.2011.564694. Epub 2011 Apr 4.

PMID:
21463129
37.

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.

Paiva B, Pérez-Andrés M, Vídriales MB, Almeida J, de las Heras N, Mateos MV, López-Corral L, Gutiérrez NC, Blanco J, Oriol A, Hernández MT, de Arriba F, de Coca AG, Terol MJ, de la Rubia J, González Y, Martín A, Sureda A, Schmidt-Hieber M, Schmitz A, Johnsen HE, Lahuerta JJ, Bladé J, San-Miguel JF, Orfao A; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas); Myeloma Stem Cell Network (MSCNET).

Leukemia. 2011 Apr;25(4):697-706. doi: 10.1038/leu.2010.320. Epub 2011 Jan 21.

PMID:
21252988
38.

Induction of B-chronic lymphocytic leukemia cell apoptosis by arsenic trioxide involves suppression of the phosphoinositide 3-kinase/Akt survival pathway via c-jun-NH2 terminal kinase activation and PTEN upregulation.

Redondo-Muñoz J, Escobar-Díaz E, Hernández Del Cerro M, Pandiella A, Terol MJ, García-Marco JA, García-Pardo A.

Clin Cancer Res. 2010 Sep 1;16(17):4382-91. doi: 10.1158/1078-0432.CCR-10-0072. Epub 2010 Jun 9.

39.

Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain.

Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernández del Cerro M, Roderfeld M, Roeb E, Opdenakker G, García-Marco JA, García-Pardo A.

Cancer Cell. 2010 Feb 17;17(2):160-72. doi: 10.1016/j.ccr.2009.12.044.

40.

VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration.

Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, Del Cerro MH, García-Marco JA, Terol MJ, García-Pardo A.

Blood. 2010 Jan 28;115(4):846-9. doi: 10.1182/blood-2009-08-239426. Epub 2009 Nov 19.

41.

Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.

Bosch F, Abrisqueta P, Villamor N, Terol MJ, González-Barca E, Ferra C, González Diaz M, Abella E, Delgado J, Carbonell F, García Marco JA, Escoda L, Ferrer S, Monzó E, González Y, Estany C, Jarque I, Salamero O, Muntañola A, Montserrat E.

J Clin Oncol. 2009 Sep 20;27(27):4578-84. doi: 10.1200/JCO.2009.22.0442. Epub 2009 Aug 24.

PMID:
19704063
42.

Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.

Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group.

J Clin Oncol. 2008 Jun 1;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. Epub 2008 Apr 28.

PMID:
18443352
43.

Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells.

Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, del Cerro MH, Van den Steen PE, Opdenakker G, Terol MJ, García-Pardo A.

Blood. 2008 Jul 1;112(1):169-78. doi: 10.1182/blood-2007-08-109249. Epub 2008 Mar 7.

44.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5.

45.

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.

Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ; Spanish Myeloma Group/PETHEMA.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54.

46.

[Primary liver lymphoma in a patient with hepatitis C].

Martínez García F, Fábia Valls MJ, Mayordomo Aranda E, Terol MJ.

Med Clin (Barc). 2007 May 12;128(18):718-9. Spanish. No abstract available.

PMID:
17540154
47.

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.

Guillem VM, Collado M, Terol MJ, Calasanz MJ, Esteve J, Gonzalez M, Sanzo C, Nomdedeu J, Bolufer P, Lluch A, Tormo M.

Leukemia. 2007 Jul;21(7):1413-22. Epub 2007 May 3.

PMID:
17476281
48.

Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.

Jantus-Lewintre E, Sarsotti E, Terol MJ, Benet I, García-Conde J.

Clin Transl Oncol. 2006 Nov;8(11):805-11.

PMID:
17134969
49.

MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration.

Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, Terol MJ, García-Marco JA, García-Pardo A.

Blood. 2006 Nov 1;108(9):3143-51. Epub 2006 Jul 13.

50.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Blood. 2006 Oct 1;108(7):2165-72. Epub 2006 Jun 13.

Supplemental Content

Loading ...
Support Center